GSK settles HIV drug licensing dispute

GSK subsidiary and Exavir Therapeutics end dispute over licensing rights for HIV-drug compounds | Resolution follows allegations that Exavir's actions disrupted ViiV Healthcare's research collaboration with a US university.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

GSK settles second Zantac case in a month in California amid slew of US litigation

29 February 2024 Firm wishes to avoid ‘protracted litigation’ with confidential settlement | Counsel for GSK told Delaware judge in January that lawsuits are ‘way ahead of the science’.

Big Pharma

GSK gets appeal go-ahead in licensing clash with AZ

13 February 2024 Appeals court sides with GSK unit in licensing dispute over ovarian cancer drug | Judges find fault with previous decision ordering the pharma firm to pay royalties on all sales of an ovarian cancer treatment.

More on this story

Big Pharma

GSK settles second Zantac case in a month in California amid slew of US litigation

29 February 2024 Firm wishes to avoid ‘protracted litigation’ with confidential settlement | Counsel for GSK told Delaware judge in January that lawsuits are ‘way ahead of the science’.

Big Pharma

GSK gets appeal go-ahead in licensing clash with AZ

More on this story

Big Pharma

GSK settles second Zantac case in a month in California amid slew of US litigation

29 February 2024 Firm wishes to avoid ‘protracted litigation’ with confidential settlement | Counsel for GSK told Delaware judge in January that lawsuits are ‘way ahead of the science’.

Big Pharma

GSK gets appeal go-ahead in licensing clash with AZ